754219-01-7

Usage

Uses

Used in Organic Synthesis:
Ethyl 5-iodo-1-methyl-1H-pyrazole-4-carboxylate is used as a key intermediate for the synthesis of a wide range of organic molecules. Its unique structure, including the iodine atom, makes it a versatile building block that can be further functionalized to create diverse organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethyl 5-iodo-1-methyl-1H-pyrazole-4-carboxylate is utilized as a precursor in the preparation of pharmaceutical compounds. Its structural features contribute to the development of new drugs with potential therapeutic applications.
Used in Pharmaceutical Industry:
Ethyl 5-iodo-1-methyl-1H-pyrazole-4-carboxylate is used as a chemical intermediate for the production of various pharmaceuticals. Its reactivity and solubility properties make it suitable for use in the synthesis of drugs that target a range of medical conditions.
Used in Research and Development:
Ethyl 5-iodo-1-methyl-1H-pyrazole-4-carboxylate is also employed in research and development settings, where it aids scientists in exploring new chemical reactions and pathways, potentially leading to the discovery of novel pharmaceutical agents and materials.

Upstream product

• 31037-02-2 ethyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate 
• 1260243-04-6 ethyl 5-amino-1H-pyrazole-4-carboxylate 
• 74-88-4 methyl iodide 
• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 

Downstream Products

• 1198113-11-9 5-iodo-1-methyl-1H-pyrazole-4-carboxylic acid 

Relevant academic research and scientific papers

AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES

Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF

The invention provides novel compounds having RIP1 kinase inhibitory activity, pharmaceutical compositions including the compounds and methods of using the compounds.

Pd/C-mediated synthesis of α-pyrone fused with a five-membered nitrogen heteroaryl ring: A new route to pyrano[4,3-c]pyrazol-4(1H)-ones

Pd/C-mediated alkynylation of 5-iodo-pyrazole-4-carboxylic acid, involving the first regioselective construction of α-pyrone ring on a pyrazol moiety via tandem coupling-cyclization process, has been developed to afford pyrano[4,3-c]pyrazol-4(1H)-one in a

NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT

A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring "A" is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, "B" is alkylene, R1 and R2, the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.